- Home
- RERE vs GHRS Comparison
RERE vs GHRS Comparison
Compare RERE & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | GHRS |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | China | Ireland |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.6M | 947.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RERE | GHRS |
|---|---|---|
| Price | $4.89 | $21.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $41.38 |
| AVG Volume (30 Days) | ★ 796.8K | 120.6K |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.13 | N/A |
| Revenue Next Year | $23.08 | N/A |
| P/E Ratio | $34.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.06 | $8.75 |
| 52 Week High | $6.47 | $19.51 |
Technical Indicators
Market Signals| Indicator | RERE | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 81.31 |
| Support Level | $4.06 | $12.44 |
| Resistance Level | $6.31 | N/A |
| Average True Range (ATR) | 0.21 | 1.18 |
| MACD | 0.08 | 0.64 |
| Stochastic Oscillator | 65.73 | 71.90 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.